ReviewCureus2025
Clinical Effectiveness of Oral Relugolix in Advanced Prostate Cancer: A Structured Review of Current Primary Research.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shared decision-making in prostate cancer treatment: selecting an androgen deprivation therapy option.Future oncology (London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Relugolix is a novel orally administered gonadotropin-releasing hormone (GnRH) antagonist approved for androgen deprivation therapy (ADT) in advanced prostate cancer. Its oral formulation, rapid onset of action, and potentially improved cardiovascular safety profile distinguish it from traditional injectable GnRH antagonists. This review evaluates current primary research on the clinical effectiveness and safety of Relugolix compared to established ADT agents. A structured literature search was conducted using PubMed, targeting primary research articles that assessed the efficacy and safety of oral Relugolix. Inclusion criteria comprised original studies with clinical endpoints such as testosterone suppression, prostate-specific antigen (PSA) response, and castration resistance-free survival (CRFS). Exclusion criteria included reviews, meta-analyses, and studies not investigating Relugolix. Searches were completed by two independent reviewers compared following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Nine primary studies met the inclusion criteria, including randomized controlled trials (RCTs), subgroup analyses, pharmacokinetic modelling, and observational studies. In the HERO trial, Relugolix achieved castration-level testosterone (<50 ng/dL) in 96.7% of patients, outperforming Leuprolide (88.3%) in both speed (median = 4 days vs. 29 days) and magnitude of suppression. Subgroup analyses demonstrated consistent efficacy across patients receiving concomitant therapies with a lower incidence of major cardiovascular events in the Relugolix group. Additional studies confirmed its effectiveness when combined with radiotherapy in comparison with Degarelix. Pharmacokinetic modelling supported rapid and sustained testosterone suppression even during short treatment interruptions. Relugolix is an effective and well-tolerated oral GnRH antagonist for patients with advanced prostate cancer. It offers rapid testosterone suppression, high rates of CRFS, and a potentially favorable cardiovascular safety profile compared to injectable ADT agents. These advantages, along with oral administration, support its use as a viable alternative in clinical practice. Further long-term studies are warranted to confirm sustained outcomes and optimize treatment regimes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.